CRNX
insider transactionsCrinetics Pharmaceuticals, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-151.8K
0 buy · 151.8K sell
Net value · 365d
-$6.0M
$0 in · $6.0M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
14
0 buy · 151.8K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Director · 10b5-1
$22.0K
608 sh · $36.22
Own -9%
-
Sell·S
Director · 10b5-1
$224.1K
6.3K sh · $35.62
Own -47%
-
Other·G
President & CEO
$0
111.1K sh
Own -18%
-
Other·G
President & CEO
$0
80.0K sh
Own -37%
-
Other·G
President & CEO
$0
222.2K sh
Own -34%
-
Exercise·M
Chief Dev. & Operating Officer · 10b5-1
$0
19.3K sh
Own +41%
-
Exercise·M
Chief Dev. & Operating Officer · 10b5-1
$0
9.6K sh
Own +997%
-
Exercise·M
Chief Dev. & Operating Officer · 10b5-1
$0
49.5K sh
Own +365%
-
Sell·S
Chief Dev. & Operating Officer · 10b5-1
$3.4M
85.2K sh · $40.10
Own -45%
-
Exercise·M
Chief Dev. & Operating Officer · 10b5-1
$379.8K
19.3K sh · $19.64
Own +11%
-
Exercise·M
Chief Dev. & Operating Officer · 10b5-1
$192.7K
9.6K sh · $20.02
Own +6%
-
Exercise·M
Chief Dev. & Operating Officer · 10b5-1
$1.2M
49.5K sh · $23.98
Own +44%
-
Sell·S
Chief Operating Officer · 10b5-1
$149.6K
4.0K sh · $37.77
Own -3%
-
Sell·S
Chief Operating Officer · 10b5-1
$220.8K
6.0K sh · $37.11
Own -5%
-
Sell·S
President & CEO · 10b5-1
$331.8K
8.8K sh · $37.77
Own -2%
-
Sell·S
President & CEO · 10b5-1
$489.7K
13.2K sh · $37.11
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$160.2K
4.2K sh · $37.77
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$236.4K
6.4K sh · $37.11
Own -4%
-
Sell·S
Director · 10b5-1
$19.2K
523 sh · $36.77
Own -3%
-
Sell·S
Director · 10b5-1
$161.5K
4.5K sh · $36.08
Own -21%
-
Sell·S
Director · 10b5-1
$119.0K
3.0K sh · $39.67
Own -18%
-
Sell·S
Tobin Schilke KEY
Chief Financial Officer · 10b5-1
$266.3K
6.7K sh · $39.67
Own -8%
-
Grant·A
President & CEO
$0
228.0K sh
Own New
-
Grant·A
President & CEO
$0
62.0K sh
Own +17%
-
Grant·A
Tobin Schilke KEY
Chief Financial Officer
$0
50.0K sh
Own New
-
Grant·A
Tobin Schilke KEY
Chief Financial Officer
$0
32.0K sh
Own +61%
-
Grant·A
Chief Operating Officer
$0
55.0K sh
Own New
-
Grant·A
Chief Operating Officer
$0
34.0K sh
Own +39%
-
Grant·A
Chief Commercial Officer
$0
55.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
34.0K sh
Own +4077%
-
Grant·A
Chief Scientific Officer
$0
47.0K sh
Own New
-
Grant·A
Chief Scientific Officer
$0
30.0K sh
Own +25%
-
Exercise·M
Chief Commercial Officer · 10b5-1
$0
2.5K sh
Own +3%
-
Sell·S
Chief Commercial Officer · 10b5-1
$137.5K
2.5K sh · $55.00
Own -75%
-
Exercise·M
Chief Commercial Officer · 10b5-1
$101.5K
2.5K sh · $40.59
Own +300%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 17, 2026 | Stephanie Okey 10b5-1 | Sell S | 608 | $22.0K |
| Jun 17, 2026 | Stephanie Okey 10b5-1 | Sell S | 6.3K | $224.1K |
| May 29, 2026 | Richard Scott Struthers KEY | Other G | 111.1K | $0 |
| May 29, 2026 | Richard Scott Struthers KEY | Other G | 80.0K | $0 |
| May 29, 2026 | Richard Scott Struthers KEY | Other G | 222.2K | $0 |
| Apr 8, 2026 | Jeff E. Knight 10b5-1 | Exercise M | 19.3K | $0 |
| Apr 8, 2026 | Jeff E. Knight 10b5-1 | Exercise M | 9.6K | $0 |
| Apr 8, 2026 | Jeff E. Knight 10b5-1 | Exercise M | 49.5K | $0 |
| Apr 8, 2026 | Jeff E. Knight 10b5-1 | Sell S | 85.2K | $3.4M |
| Apr 8, 2026 | Jeff E. Knight 10b5-1 | Exercise M | 19.3K | $379.8K |
| Apr 8, 2026 | Jeff E. Knight 10b5-1 | Exercise M | 9.6K | $192.7K |
| Apr 8, 2026 | Jeff E. Knight 10b5-1 | Exercise M | 49.5K | $1.2M |
| Mar 16, 2026 | Jeff E. Knight 10b5-1 | Sell S | 4.0K | $149.6K |
| Mar 16, 2026 | Jeff E. Knight 10b5-1 | Sell S | 6.0K | $220.8K |
| Mar 16, 2026 | Richard Scott Struthers KEY 10b5-1 | Sell S | 8.8K | $331.8K |
| Mar 16, 2026 | Richard Scott Struthers KEY 10b5-1 | Sell S | 13.2K | $489.7K |
| Mar 16, 2026 | Stephen F. Betz 10b5-1 | Sell S | 4.2K | $160.2K |
| Mar 16, 2026 | Stephen F. Betz 10b5-1 | Sell S | 6.4K | $236.4K |
| Mar 12, 2026 | Coelho Rogerio Vivaldi 10b5-1 | Sell S | 523 | $19.2K |
| Mar 12, 2026 | Coelho Rogerio Vivaldi 10b5-1 | Sell S | 4.5K | $161.5K |
| Mar 3, 2026 | Stephanie Okey 10b5-1 | Sell S | 3.0K | $119.0K |
| Mar 3, 2026 | Tobin Schilke KEY 10b5-1 | Sell S | 6.7K | $266.3K |
| Feb 23, 2026 | Richard Scott Struthers KEY | Grant A | 228.0K | $0 |
| Feb 23, 2026 | Richard Scott Struthers KEY | Grant A | 62.0K | $0 |
| Feb 23, 2026 | Tobin Schilke KEY | Grant A | 50.0K | $0 |
| Feb 23, 2026 | Tobin Schilke KEY | Grant A | 32.0K | $0 |
| Feb 23, 2026 | Jeff E. Knight | Grant A | 55.0K | $0 |
| Feb 23, 2026 | Jeff E. Knight | Grant A | 34.0K | $0 |
| Feb 23, 2026 | Isabel Kalofonos | Grant A | 55.0K | $0 |
| Feb 23, 2026 | Isabel Kalofonos | Grant A | 34.0K | $0 |
| Feb 23, 2026 | Stephen F. Betz | Grant A | 47.0K | $0 |
| Feb 23, 2026 | Stephen F. Betz | Grant A | 30.0K | $0 |
| Jan 5, 2026 | Isabel Kalofonos 10b5-1 | Exercise M | 2.5K | $0 |
| Jan 5, 2026 | Isabel Kalofonos 10b5-1 | Sell S | 2.5K | $137.5K |
| Jan 5, 2026 | Isabel Kalofonos 10b5-1 | Exercise M | 2.5K | $101.5K |
About CRNX insider trading
This page tracks insider transactions for Crinetics Pharmaceuticals, Inc. (CRNX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.